Suggestions
Mads Hald Andersen
Director, Professor at National Center for Cancer Immune Therapy
Mads Hald Andersen is a prominent figure in cancer immunotherapy research and a leader in the field. He is the Director and Professor at the Center for Cancer Immune Therapy (CCIT) at Herlev University Hospital in Denmark.14
Academic Background and Achievements
Professor Andersen has an impressive academic background:
- He obtained his DScTech (Doctor of Technical Sciences) in 2006
- He earned his DMSc (Doctor of Medical Sciences) in 20161
Throughout his career, Professor Andersen has received several prestigious awards, including:
- The Lundbeck Foundation research prize (2012)
- The Danish Cancer Society Research Award (2006)
- The Hallas-Møller Stipend (2007)1
Research Focus and Contributions
Professor Andersen's research primarily focuses on characterizing natural immune responses to malignant cells.3 His work has led to significant advancements in the field of cancer immunotherapy:
- He has identified several T-cell antigens, including survivin, the Bcl-2 family, and RhoC
- These discoveries have formed the basis for ongoing clinical trials in Europe and the USA
- Survivin, one of his identified antigens, is now one of the most commonly used cancer antigens worldwide1
Recently, Professor Andersen initiated a new research program focusing on antigen-specific immune regulation, specifically studying IDO and PD-L1.1
Professional Experience and Roles
- 2015-present: Professor at Copenhagen University2
- 2006-present: Vice-Director and co-Founder of the Center for Cancer Immunotherapy (CCIT) at the University Hospital Herlev2
- He has considerable pharmaceutical experience and has founded several biotech companies, including IO Biotech Aps1
Publications and Patents
Professor Andersen has an extensive publication record:
- Over 150 publications in peer-reviewed journals
- More than 15 patents
- Several book chapters1
His work has garnered significant attention in both scientific and popular media, with his publications often accompanied by commentaries and articles.1
Highlights
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy: https://lnkd.in/dQ4PwePK
Congratulations and thanks to Rasmus Mortensen, Morten Orebo Holmström , Thomas Landkildehus Lisle, @Jane P Hasselby, @Gro L Willemoe, Özcan Met Inge Marie Svane, @julia Johansen, @ dorte Nielsen, Inna Chen As TGFβ-based vaccination with ICI/radiotherapy may be beneficial for patients with pancreatic cancer we are starting a clinical trial at https://lnkd.in/dMx7kjET
We are very happy to have shown that the immunosuppressive microenvironment in pancreatic cancer can be successfully targeted by a TGFβ-derived immune modulatory vaccine in animal models - a very important step before we go into patients next year! Please see more: https://lnkd.in/e82azFxN # #
Congratulations María Pérez Penco and co-authors Stine Emilie Weis-Banke Aimilia Schina Majken Storm Siersbæk Mie Linder Hübbe Mia Aaboe Jørgensen Inés Lecoq Molinos Lucía Lara de la Torre Simone Kloch Bendtsen Evelina Martinenaite Morten Orebo Holmström Daniel H. Madsen Marco Donia Niels Ødum Lars Grøntved #ccit-dk #immunemodulatoryvaccine #pancreaticcancer
